Press releases Archieven – Droia Ventures

19 Jul Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline

Posted at 12:00h in Frontier Medicines, Press releases

Funding to Enhance Research and Development of Pipeline, Including Lead Program Targeting Activated KRAS^G12C. Proceeds to Further Accelerate the Development of Foundational Technologies in Chemoproteomics, Covalent Drug Discovery and Machine Learning. Distinguished Scientific Advisory Board Announced. Expansion of Frontier Operations with Opening of Boston Facility...

17 Jun Cyteir Therapeutics Announces Pricing of Initial Public Offering

Posted at 11:23h in Cyteir Therapeutics, Geen categorie, Press releases

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cyteir, are expected to be approximately $133 million excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on...

18 May Hummingbird Bioscience Raises US$125 Million in Series C Financing

Posted at 14:02h in Hummingbird Bioscience, Press releases

“We are delighted to have the support and confidence of leading global healthcare investors to advance the development of our unique pipeline of precision therapies against important, yet hard-to-drug targets. We have made tremendous progress since closing our Series B in 2019 and this financing...

11 May Droia Ventures raises a new fund of EUR 220 million to target genetic diseases and expands leadership team with George Golumbeski

Posted at 14:13h in Droia Ventures, Press releases

George Golumbeski has joined the Droia partnership to reinforce the team with the launch of the new fund. Golumbeski is the former Executive Vice President of Business Development at Celgene, where he was a major architect of Celgene’s successful biotech collaboration and acquisition strategy. Post...

06 Apr Volastra Therapeutics extends seed financing to $44 million to advance drug discovery programs to prevent cancer metastasis

Posted at 14:30h in Press releases, Volastra Therapeutics

“The support of our new and existing investors reflects the increasing interest around CIN as a core driver in cancer biology,” said Charles Hugh-Jones, M.D., Volastra’s Chief Executive Officer. “This latest financing places us in a position of strength to advance our bold vision to...

11 Feb Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program

Posted at 13:54h in Cyteir Therapeutics, Press releases

“We are intrigued by the potential of RAD-51 inhibition, particularly due to early findings suggesting it could be helpful in treating lymphomas and other hematologic malignancies,” said Derek DiRocco, Ph.D., partner, RA Capital Management. “This promising mechanism, coupled with the demonstrated efficiency and expertise of...

05 Jan Aura Biosciences Appoints David Johnson to Its Board of Directors

Posted at 14:08h in Aura Biosciences, Press releases

With David’s impressive track record in oncology and as an accomplished CEO, his engagement and guidance will help Aura drive AU-011 for the treatment of choroidal melanoma to registration and commercialization,” said George Golumbeski, Ph.D., Chairman of the Board of Aura Biosciences....

11 Dec QurAlis’ selective Kv7 opener, a drug candidate for ALS, demonstrates up to 20-fold increase in potency and dramatic reduction in side effects compared to Retigabine in preclinical models

Posted at 18:18h in Press releases, QurAlis

QurAlis' announces the results of extensive pre-clinical studies on its lead program for ALS patients: QRA-244 shows comparable effects to retigabine and dramatic reductions in side effects....

02 Dec Frontier Medicines and AbbVie establish global partnership to discover and develop novel therapies and E3 degraders against difficult-to-drug targets

Posted at 22:08h in Frontier Medicines, Press releases

Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases. Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration....

29 Oct QurAlis Announces Appointment of new Chief Medical Officer and Formation of Clinical Advisory Board

Posted at 09:43h in Press releases, QurAlis

The company also announced the formation of its Clinical Advisory Board, which will work closely with Dr. Genge on QurAlis’ clinical research and development programs in ALS and frontotemporal dementia (FTD) as the company prepares to move its pipeline to the clinical stage....